Clinical Validation Reached in Phase 2a Trial of AX-158 for Psoriasis
Image Credit: © fusssergei – stock.adobe.com Artax announced today that clinical validation was reached in a phase 2a trial of AX-158, a fully proprietary oral agent for the treatment of psoriasis.1 These results confirm both preclinical data and phase 1 findings. The first patient was dosed with this novel mechanism for mild to moderate plaque … Read more